

March 12, 2020

The Manager- Listing
BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Sub: AstraZeneca Pharma India Limited receives Import and Market Permission in Form CT-20 (Marketing Authorization – Additional Indication) from Drug Controller General of India (DCGI) for Acalabrutinib 100mg capsules (Calquence®)


This is to inform that AstraZeneca Pharma India Limited has received Import and Market permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Acalabrutinib 100mg capsules (Calquence®).

The receipt of this Import and Market permission paves way for the launch of Acalabrutinib 100mg capsules (Calquence®) in India, subject to the receipt of related statutory approvals and licenses.

Acalabrutinib 100mg capsules is indicated for treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).

Kindly take the same on record.

For AstraZeneca Pharma India Limited



Pratap Rudra
Company Secretary & Legal Counsel

